Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of [13C]Pyruvate as an Imaging Agent for Magnetic Resonance Imaging in Healthy Volunteers
Sponsor: Memorial Sloan Kettering Cancer Center
Summary
The purpose of the study is to learn about the use of \[13C\]pyruvate as an imaging agent for MRI scans. In past studies, researchers have seen that \[13C\]pyruvate can improve imaging with MRI scans. However, they would like to know more about how the imaging agent is distributed in healthy organs and tissues. This study will provide additional information about the use of \[13C\]pyruvate as an imaging agent for MRI scans, and it will show us how the substance is metabolized (changed into energy) in the organs and tissues of healthy volunteers. For (n=5) volunteers undergoing brain imaging we will compare the standard injection at 5mL/second with a slower infusion (0.1-1mL/second) to achieve a 60 second infusion time, to approach quasi steady-state metabolism and improve SNR.
Official title: Optimized In-Human [13C]Pyruvate MRI For Assessment Of Physiologic Reference Data In Different Organs
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2021-09-01
Completion Date
2026-09
Last Updated
2026-02-20
Healthy Volunteers
Yes
Conditions
Interventions
Hyperpolarized [13C] Pyruvate
Will be injected at a dosage of 0.43 ± 0.05 mL/kg body weight
Locations (1)
Memorial Sloan Kettering Cancer Center
New York, New York, United States